VA NEPHRON D Trial Explained: Why Dual RAAS Blockade Failed

VA NEPHRON D tested whether adding lisinopril to losartan would improve kidney outcomes in patients with type 2 diabetes, overt proteinuric diabetic kidney disease, and estimated GFR 30 to 89.9. Although albuminuria improved, the trial did not significantly reduce the primary composite outcome and increased acute kidney injury and hyperkalemia. This Nephrology Notebook episode reviews the clinical dilemma, RAAS physiology, trial design, efficacy results, safety signals, limitations, and modern practice implications. Based on Fried LF et al, Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy, New England Journal of Medicine, 2013. This video is for education only and is not individualized medical advice. Kevin is a hypothetical teaching case and does not represent a real patient. Key Points 1. VA NEPHRON D tested dual RAAS blockade in a high risk diabetic kidney disease population with overt proteinuria. 2. Adding lisinopril to losartan lowered albuminuria but did not significantly reduce the primary composite outcome. 3. Hyperkalemia and acute kidney injury increased substantially with combination therapy. 4. The trial was stopped early because serious adverse event risk outweighed potential benefit. 5. The core teaching point is to treat the patient, not only the surrogate marker. 6. Routine ACE inhibitor plus ARB dual blockade should be avoided in proteinuric diabetic kidney disease.